Glenmark Pharma acquires ANDAs from Wockhardt

Glenmark Pharma acquires ANDAs from Wockhardt

by admin- Tuesday, June 28th, 2022 03:53:08 PM

Glenmark Pharmaceuticals announced that its completely owned subsidiary Glenmark Pharmaceuticals Inc., USA (Glenmark) has obtained the authorised Abbreviated New Drug Applications (ANDAs) for Famotidine Tablets USP, 10 mg and 20 mg (OTC), Cetirizine Hydrochloride Tablets USP, 5 mg and 10 mg (OTC), Lansoprazole DelayedRelease Capsules USP, 15 mg (OTC) and Olopatadine Hydrochloride Ophthalmic Solution USP, zero.1% (OTC) in the United States from Wockhardt Ltd.

News Updates